• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服β-肾上腺素能阻滞剂的术前使用与心脏手术后新发房颤的发生率。一项系统评价和荟萃分析。

Preoperative Use of Oral Beta-Adrenergic Blocking Agents and the Incidence of New-Onset Atrial Fibrillation After Cardiac Surgery. A Systematic Review and Meta-Analysis.

作者信息

Thein Paul Min, White Kyle, Banker Khyati, Lunny Carole, Mirzaee Sam, Nasis Arthur

机构信息

Department of Medicine, Monash Medical Centre, Monash Health, Melbourne, Vic, Australia; Monash University, School of Public Health and Preventive Medicine, Melbourne, Vic, Australia.

Monash University, School of Public Health and Preventive Medicine, Melbourne, Vic, Australia.

出版信息

Heart Lung Circ. 2018 Mar;27(3):310-321. doi: 10.1016/j.hlc.2017.08.026. Epub 2017 Oct 19.

DOI:10.1016/j.hlc.2017.08.026
PMID:29129562
Abstract

BACKGROUND

Current epidemiological data suggests that postoperative atrial fibrillation or atrial flutter (POAF) causes significant morbidity and mortality after cardiac surgery. The literature for prophylactic management of POAF is limited, resulting in the lack of clear guidelines on management recommendations.

AIM

To examine the efficacy of prophylactic rate control agents in reducing the incidence of new-onset POAF in patients undergoing elective cardiac surgery.

METHODS

Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and Medline were systematically searched for blinded randomised controlled studies (RCT) evaluating adults with no history of atrial fibrillation randomised to a pharmacological agent (either beta blocker, calcium channel blocker or digoxin), compared to placebo. Utilising Cochrane guidance, three reviewers screened, extracted and the quality of the evidence was assessed. We used a random effects meta-analysis to compare a rate-control agent with placebo.

RESULTS

Five RCTs (688 subjects, mean age 61±8.9, 69% male) were included. Beta blocker administration prior to elective cardiac surgery significantly reduced the incidence of POAF (OR 0.43, 95%Cl [0.30-0.61], I=0%) without significant impact on ischaemic stroke (OR 0.49, 95%Cl [0.10-2.44], I=0%), non-fatal myocardial infarction (OR 0.76, 95%Cl [0.08-7.44], I=0%), overall mortality (OR 0.83, 95%Cl [0.19-3.66], I=0%), or length of stay (mean -0.96days 95%Cl [-1.49 to -0.42], I=0%). An increased rate of bradycardic episodes was observed (OR 3.53, 95%Cl [1.22-10.23], I=0%).

CONCLUSIONS

This review suggests that selective administration of prophylactic oral beta blockers prior to elective cardiac surgery is safe and may reduce the incidence of POAF.

摘要

背景

目前的流行病学数据表明,心脏手术后发生的房颤或房扑(POAF)会导致显著的发病率和死亡率。关于POAF预防性管理的文献有限,导致缺乏明确的管理建议指南。

目的

研究预防性心率控制药物在降低择期心脏手术患者新发POAF发生率方面的疗效。

方法

系统检索Cochrane对照试验中心注册库(CENTRAL)、Embase和Medline,查找评估无房颤病史的成年人随机接受药物治疗(β受体阻滞剂、钙通道阻滞剂或地高辛)与安慰剂对照的双盲随机对照研究(RCT)。按照Cochrane指南,三名 reviewers 进行筛选、提取并评估证据质量。我们使用随机效应荟萃分析来比较心率控制药物与安慰剂。

结果

纳入了五项RCT(688名受试者,平均年龄61±8.9岁,69%为男性)。择期心脏手术前给予β受体阻滞剂可显著降低POAF的发生率(OR 0.43,95%CI [0.30 - 0.61],I = 0%),对缺血性卒中(OR 0.49,95%CI [0.10 - 2.44],I = 0%)、非致命性心肌梗死(OR 0.76,95%CI [0.08 - 7.44],I = 0%)、总体死亡率(OR 0.83,95%CI [0.19 - 3.66],I = 0%)或住院时间(平均 - 0.96天,95%CI [- 1.49至 - 0.42],I = 0%)无显著影响。观察到心动过缓发作率增加(OR 3.53,95%CI [1.22 - 10.23],I = 0%)。

结论

本综述表明,择期心脏手术前选择性给予预防性口服β受体阻滞剂是安全的,可能会降低POAF的发生率。

相似文献

1
Preoperative Use of Oral Beta-Adrenergic Blocking Agents and the Incidence of New-Onset Atrial Fibrillation After Cardiac Surgery. A Systematic Review and Meta-Analysis.口服β-肾上腺素能阻滞剂的术前使用与心脏手术后新发房颤的发生率。一项系统评价和荟萃分析。
Heart Lung Circ. 2018 Mar;27(3):310-321. doi: 10.1016/j.hlc.2017.08.026. Epub 2017 Oct 19.
2
Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis.肺手术后预防心房颤动的药物干预:系统评价和荟萃分析。
Eur J Clin Pharmacol. 2022 Nov;78(11):1777-1790. doi: 10.1007/s00228-022-03383-2. Epub 2022 Sep 22.
3
Perioperative beta-blockers for preventing surgery-related mortality and morbidity.围手术期使用β受体阻滞剂预防手术相关的死亡率和发病率。
Cochrane Database Syst Rev. 2018 Mar 13;3(3):CD004476. doi: 10.1002/14651858.CD004476.pub3.
4
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
5
Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants.β受体阻滞剂用于预防和治疗早产儿视网膜病变
Cochrane Database Syst Rev. 2018 Mar 2;3(3):CD011893. doi: 10.1002/14651858.CD011893.pub2.
6
Efficacy of N-acetylcysteine in reducing the risk of postoperative atrial fibrillation in cardiothoracic surgery: a systematic review and meta-analysis of randomized controlled trials.N-乙酰半胱氨酸降低心胸外科手术后房颤风险的疗效:一项随机对照试验的系统评价和荟萃分析
Minerva Cardiol Angiol. 2025 Jun;73(3):387-396. doi: 10.23736/S2724-5683.24.06482-2. Epub 2024 Jun 5.
7
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.心脏手术患者术后房颤的预防干预措施。
Cochrane Database Syst Rev. 2004 Oct 18(4):CD003611. doi: 10.1002/14651858.CD003611.pub2.
8
N-3 polyunsaturated fatty acids for prevention of postoperative atrial fibrillation: updated meta-analysis and systematic review.N-3多不饱和脂肪酸预防术后心房颤动:更新的荟萃分析和系统评价
J Interv Card Electrophysiol. 2018 Mar;51(2):105-115. doi: 10.1007/s10840-018-0315-5. Epub 2018 Jan 29.
9
Beta-blockers in patients without heart failure after myocardial infarction.心肌梗死后无心力衰竭的患者使用β受体阻滞剂。
Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD012565. doi: 10.1002/14651858.CD012565.pub2.
10
Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.非 ICU 住院患者预防谵妄的非药物干预措施。
Cochrane Database Syst Rev. 2021 Nov 26;11(11):CD013307. doi: 10.1002/14651858.CD013307.pub3.

引用本文的文献

1
Prediction Model for POstoperative atriaL fibrillAtion in caRdIac Surgery: The POLARIS Score.心脏手术术后心房颤动的预测模型:北极星评分
J Clin Med. 2025 Jan 20;14(2):650. doi: 10.3390/jcm14020650.
2
An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation.超短效β1选择性拮抗剂兰地洛尔在心房颤动中的药代动力学和药效学概述
Pharmaceutics. 2024 Apr 8;16(4):517. doi: 10.3390/pharmaceutics16040517.
3
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review.
钠-葡萄糖共转运蛋白 2 抑制剂可能无法预防心力衰竭患者的心房颤动:系统评价。
Cardiovasc Diabetol. 2023 May 24;22(1):124. doi: 10.1186/s12933-023-01860-1.
4
Development and validation of a nomogram for predicting atrial fibrillation in patients with acute heart failure admitted to the ICU: a retrospective cohort study.开发和验证 ICU 收治的急性心力衰竭患者房颤预测列线图:一项回顾性队列研究。
BMC Cardiovasc Disord. 2022 Dec 6;22(1):528. doi: 10.1186/s12872-022-02973-3.
5
Genetic and non-genetic risk factors associated with atrial fibrillation.与心房颤动相关的遗传和非遗传风险因素。
Life Sci. 2022 Jun 15;299:120529. doi: 10.1016/j.lfs.2022.120529. Epub 2022 Apr 3.
6
New-Onset Atrial Fibrillation in Adult Patients After Cardiac Surgery.心脏手术后成年患者新发心房颤动
Curr Anesthesiol Rep. 2019 Jun;9(2):174-193. doi: 10.1007/s40140-019-00321-4. Epub 2019 Apr 24.
7
Contemporary personalized β-blocker management in the perioperative setting.围手术期的当代个性化β受体阻滞剂管理。
J Anesth. 2020 Feb;34(1):115-133. doi: 10.1007/s00540-019-02691-9. Epub 2019 Oct 21.
8
Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery.围手术期使用β受体阻滞剂预防心脏手术成年患者的手术相关死亡率和发病率。
Cochrane Database Syst Rev. 2019 Sep 23;9(9):CD013435. doi: 10.1002/14651858.CD013435.
9
Prevalence and risk factors of atrial fibrillation during lung and esophageal surgery: A Prospective observational study.肺和食管手术期间心房颤动的患病率及危险因素:一项前瞻性观察研究。
Medicine (Baltimore). 2018 Jul;97(30):e11549. doi: 10.1097/MD.0000000000011549.